Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients

Publication type:
Journal article
Metadata:
Autoren
  • Wulf Siggelkow
  • Daniel Boehm
  • Susanne Gebhard
  • Marco Battista
  • Isabel Sicking
  • Antje Lebrecht
  • Christine Solbach
  • Birte Hellwig
  • Jorg Rahnenfuhrer
  • Heinz Koelbl
  • Mathias Gehrmann
  • Rosemarie Marchan
  • Cristina Cadenas
  • Jan G Hengstler
  • Marcus Schmidt
Sammlungen
  • metadata
ISSN
1471-2407
Zeitschrift
BMC cancer
Schlüsselwörter
  • 610 Medizin
  • 610 Medical sciences
Sprache
eng
Paginierung
Art. 562
Datum der Veröffentlichung
2012
Herausgeber
Springer
Herausgeber URL
http://dx.doi.org/10.1186/1471-2407-12-562
Datum der Datenerfassung
2020
Datum, an dem der Datensatz öffentlich gemacht wurde
2020
Zugang
Public
Titel
Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients
Ausgabe der Zeitschrift
12

Data source: METADATA.UB

Other metadata sources:
Autoren
  • Wulf Siggelkow
  • Daniel Boehm
  • Susanne Gebhard
  • Marco Battista
  • Isabel Sicking
  • Antje Lebrecht
  • Christine Solbach
  • Birte Hellwig
  • Joerg Rahnenfuehrer
  • Heinz Koelbl
  • Mathias Gehrmann
  • Rosemarie Marchan
  • Cristina Cadenas
  • Jan G Hengstler
  • Marcus Schmidt
Autoren-URL
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000312720700001&DestLinkType=FullRecord&DestApp=WOS_CPL
DOI
10.1186/1471-2407-12-562
eISSN
1471-2407
Externe Identifier
  • Clarivate Analytics Document Solution ID: 059QS
  • PubMed Identifier: 23186136
Zeitschrift
BMC CANCER
Schlüsselwörter
  • Aurora kinase
  • Node-negative breast cancer
  • Breast cancer
  • Prognosis
  • Aurora kinase inhibitors
Artikelnummer
ARTN 562
Datum der Veröffentlichung
2012
Status
Published
Titel
Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients
Sub types
  • Article
Ausgabe der Zeitschrift
12

Data source: Web of Science (Lite)

Abstract
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Inhibitors targeting the cell cycle-regulated aurora kinase A (AURKA) are currently being developed. Here, we examine the prognostic impact of AURKA in node-negative breast cancer patients without adjuvant systemic therapy (n = 766).</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>AURKA was analyzed using microarray-based gene-expression data from three independent cohorts of node-negative breast cancer patients. In multivariate Cox analyses, the prognostic impact of age, histological grade, tumor size, estrogen receptor (ER), and HER2 were considered.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Patients with higher AURKA expression had a shorter metastasis-free survival (MFS) in the Mainz (HR 1.93; 95% CI 1.34 – 2.78; P &lt; 0.001), Rotterdam (HR 1.95; 95% CI 1.45– 2.63; P&lt;0.001) and Transbig (HR 1.52; 95% CI 1.14–2.04; P=0.005) cohorts. AURKA was also associated with MFS in the molecular subtype ER+/HER2- carcinomas (HR 2.10; 95% CI 1.70–2.59; P&lt;0.001), but not in ER-/HER2- nor in HER2+ carcinomas. In the multivariate Cox regression adjusted to age, grade and tumor size, AURKA showed independent prognostic significance in the ER+/HER2- subtype (HR 1.73; 95% CI 1.24–2.42; P=0.001). Prognosis of patients in the highest quartile of AURKA expression was particularly poor. In addition, AURKA correlated with the proliferation metagene (R=0.880; P&lt;0.001), showed a positive association with grade (P&lt;0.001), tumor size (P&lt;0.001) and HER2 (P&lt;0.001), and was inversely associated with ER status (P&lt;0.001).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>AURKA is associated with worse prognosis in estrogen receptor positive breast carcinomas. Patients with the highest AURKA expression (&gt;75% percentile) have a particularly bad prognosis and may profit from therapy with AURKA inhibitors.</jats:p></jats:sec>
Autoren
  • Wulf Siggelkow
  • Daniel Boehm
  • Susanne Gebhard
  • Marco Battista
  • Isabel Sicking
  • Antje Lebrecht
  • Christine Solbach
  • Birte Hellwig
  • Jörg Rahnenführer
  • Heinz Koelbl
  • Mathias Gehrmann
  • Rosemarie Marchan
  • Cristina Cadenas
  • Jan G Hengstler
  • Marcus Schmidt
DOI
10.1186/1471-2407-12-562
eISSN
1471-2407
Ausgabe der Veröffentlichung
1
Zeitschrift
BMC Cancer
Sprache
en
Artikelnummer
562
Online publication date
2012
Datum der Veröffentlichung
2012
Status
Published
Herausgeber
Springer Science and Business Media LLC
Herausgeber URL
http://dx.doi.org/10.1186/1471-2407-12-562
Datum der Datenerfassung
2023
Titel
Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients
Ausgabe der Zeitschrift
12

Data source: Crossref

Abstract
<h4>Background</h4>Inhibitors targeting the cell cycle-regulated aurora kinase A (AURKA) are currently being developed. Here, we examine the prognostic impact of AURKA in node-negative breast cancer patients without adjuvant systemic therapy (n = 766).<h4>Methods</h4>AURKA was analyzed using microarray-based gene-expression data from three independent cohorts of node-negative breast cancer patients. In multivariate Cox analyses, the prognostic impact of age, histological grade, tumor size, estrogen receptor (ER), and HER2 were considered.<h4>Results</h4>Patients with higher AURKA expression had a shorter metastasis-free survival (MFS) in the Mainz (HR 1.93; 95% CI 1.34 - 2.78; P < 0.001), Rotterdam (HR 1.95; 95% CI 1.45- 2.63; P<0.001) and Transbig (HR 1.52; 95% CI 1.14-2.04; P=0.005) cohorts. AURKA was also associated with MFS in the molecular subtype ER+/HER2- carcinomas (HR 2.10; 95% CI 1.70-2.59; P<0.001), but not in ER-/HER2- nor in HER2+ carcinomas. In the multivariate Cox regression adjusted to age, grade and tumor size, AURKA showed independent prognostic significance in the ER+/HER2- subtype (HR 1.73; 95% CI 1.24-2.42; P=0.001). Prognosis of patients in the highest quartile of AURKA expression was particularly poor. In addition, AURKA correlated with the proliferation metagene (R=0.880; P<0.001), showed a positive association with grade (P<0.001), tumor size (P<0.001) and HER2 (P<0.001), and was inversely associated with ER status (P<0.001).<h4>Conclusions</h4>AURKA is associated with worse prognosis in estrogen receptor positive breast carcinomas. Patients with the highest AURKA expression (>75% percentile) have a particularly bad prognosis and may profit from therapy with AURKA inhibitors.
Addresses
  • Department of Obstetrics and Gynecology, Diakonischen Dienste Hannover GmbH, Diakoniekrankenhaus Henriettenstiftung und Diakoniekrankenhaus Friederikenstift, Hanover, Germany.
Autoren
  • Wulf Siggelkow
  • Daniel Boehm
  • Susanne Gebhard
  • Marco Battista
  • Isabel Sicking
  • Antje Lebrecht
  • Christine Solbach
  • Birte Hellwig
  • Jörg Rahnenführer
  • Heinz Koelbl
  • Mathias Gehrmann
  • Rosemarie Marchan
  • Cristina Cadenas
  • Jan G Hengstler
  • Marcus Schmidt
DOI
10.1186/1471-2407-12-562
eISSN
1471-2407
Externe Identifier
  • PubMed Identifier: 23186136
  • PubMed Central ID: PMC3530429
Open access
true
ISSN
1471-2407
Zeitschrift
BMC cancer
Schlüsselwörter
  • Humans
  • Breast Neoplasms
  • Neoplasm Metastasis
  • Lymphatic Metastasis
  • Receptor, erbB-2
  • Receptors, Estrogen
  • Prognosis
  • Disease-Free Survival
  • Middle Aged
  • Female
  • Transcriptome
  • Aurora Kinase A
  • Aurora Kinases
  • Protein Serine-Threonine Kinases
Sprache
eng
Medium
Electronic
Online publication date
2012
Open access status
Open Access
Paginierung
562
Datum der Veröffentlichung
2012
Status
Published
Publisher licence
CC BY
Datum der Datenerfassung
2012
Titel
Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients.
Sub types
  • research-article
  • Journal Article
Ausgabe der Zeitschrift
12

Files

https://bmccancer.biomedcentral.com/counter/pdf/10.1186/1471-2407-12-562 https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23186136/pdf/?tool=EBI https://europepmc.org/articles/PMC3530429?pdf=render

Data source: Europe PubMed Central

Abstract
BACKGROUND: Inhibitors targeting the cell cycle-regulated aurora kinase A (AURKA) are currently being developed. Here, we examine the prognostic impact of AURKA in node-negative breast cancer patients without adjuvant systemic therapy (n = 766). METHODS: AURKA was analyzed using microarray-based gene-expression data from three independent cohorts of node-negative breast cancer patients. In multivariate Cox analyses, the prognostic impact of age, histological grade, tumor size, estrogen receptor (ER), and HER2 were considered. RESULTS: Patients with higher AURKA expression had a shorter metastasis-free survival (MFS) in the Mainz (HR 1.93; 95% CI 1.34 - 2.78; P < 0.001), Rotterdam (HR 1.95; 95% CI 1.45- 2.63; P<0.001) and Transbig (HR 1.52; 95% CI 1.14-2.04; P=0.005) cohorts. AURKA was also associated with MFS in the molecular subtype ER+/HER2- carcinomas (HR 2.10; 95% CI 1.70-2.59; P<0.001), but not in ER-/HER2- nor in HER2+ carcinomas. In the multivariate Cox regression adjusted to age, grade and tumor size, AURKA showed independent prognostic significance in the ER+/HER2- subtype (HR 1.73; 95% CI 1.24-2.42; P=0.001). Prognosis of patients in the highest quartile of AURKA expression was particularly poor. In addition, AURKA correlated with the proliferation metagene (R=0.880; P<0.001), showed a positive association with grade (P<0.001), tumor size (P<0.001) and HER2 (P<0.001), and was inversely associated with ER status (P<0.001). CONCLUSIONS: AURKA is associated with worse prognosis in estrogen receptor positive breast carcinomas. Patients with the highest AURKA expression (>75% percentile) have a particularly bad prognosis and may profit from therapy with AURKA inhibitors.
Date of acceptance
2012
Autoren
  • Wulf Siggelkow
  • Daniel Boehm
  • Susanne Gebhard
  • Marco Battista
  • Isabel Sicking
  • Antje Lebrecht
  • Christine Solbach
  • Birte Hellwig
  • Jörg Rahnenführer
  • Heinz Koelbl
  • Mathias Gehrmann
  • Rosemarie Marchan
  • Cristina Cadenas
  • Jan G Hengstler
  • Marcus Schmidt
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/23186136
DOI
10.1186/1471-2407-12-562
eISSN
1471-2407
Externe Identifier
  • PubMed Central ID: PMC3530429
Zeitschrift
BMC Cancer
Schlüsselwörter
  • Aurora Kinase A
  • Aurora Kinases
  • Breast Neoplasms
  • Disease-Free Survival
  • Female
  • Humans
  • Lymphatic Metastasis
  • Middle Aged
  • Neoplasm Metastasis
  • Prognosis
  • Protein Serine-Threonine Kinases
  • Receptor, ErbB-2
  • Receptors, Estrogen
  • Transcriptome
Sprache
eng
Country
England
Paginierung
562
PII
1471-2407-12-562
Datum der Veröffentlichung
2012
Status
Published online
Datum, an dem der Datensatz öffentlich gemacht wurde
2013
Titel
Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients.
Sub types
  • Journal Article
Ausgabe der Zeitschrift
12

Data source: PubMed

Author's licence
CC-BY
Autoren
  • Wulf Siggelkow
  • Daniel Boehm
  • Susanne Gebhard
  • Marco Battista
  • Isabel Sicking
  • Antje Lebrecht
  • Christine Solbach
  • Birte Hellwig
  • Jorg Rahnenfuhrer
  • Heinz Koelbl
  • Mathias Gehrmann
  • Rosemarie Marchan
  • Cristina Cadenas
  • Jan G Hengstler
  • Marcus Schmidt
Hosting institution
Universitätsbibliothek Mainz
Sammlungen
  • DFG-OA-Publizieren (2012 - 2017)
Resource version
Published version
DOI
10.1186/1471-2407-12-562
Funding acknowledgements
  • DFG, Open Access-Publizieren Universität Mainz / Universitätsmedizin
File(s) embargoed
false
Open access
true
ISSN
1471-2407
Zeitschrift
BMC cancer
Schlüsselwörter
  • 610 Medizin
  • 610 Medical sciences
Sprache
eng
Open access status
Open Access
Paginierung
Art. 562
Datum der Veröffentlichung
2012
Public URL
https://openscience.ub.uni-mainz.de/handle/20.500.12030/7593
Herausgeber
Springer
Herausgeber URL
http://dx.doi.org/10.1186/1471-2407-12-562
Datum der Datenerfassung
2022
Datum, an dem der Datensatz öffentlich gemacht wurde
2022
Zugang
Public
Titel
Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients
Ausgabe der Zeitschrift
12

Files

expression_of_aurora_kinase_a-20220817163552627.pdf

Data source: OPENSCIENCE.UB

Tools